Anaplastic thyroid carcinoma with BRAF V600E mutation (~25-50% of ATC) — dabrafenib + tra...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-ATC-BRAF-V600E-ACTIONABLE`
Type	Red flag
Status	reviewed 2026-04-30 \| pending_clinical_signoff
Diseases	`DIS-THYROID-ANAPLASTIC`
Sources	`SRC-ATA-ATC-2021` `SRC-NCCN-THYROID-2025`

Red Flag Origin

Definition	Anaplastic thyroid carcinoma with BRAF V600E mutation (~25-50% of ATC) — dabrafenib + trametinib produces dramatic responses (ROAR ORR ~70%); preferred over palliative chemotherapy.
Clinical direction	intensify
Category	high-risk-biology

Trigger Logic

{
  "all_of": [
    {
      "comparator": "==",
      "finding": "BRAF_V600E",
      "threshold": true
    }
  ],
  "type": "composite_clinical"
}

Notes

ATC universally aggressive (median OS ~5-6 mo with chemo alone). BRAF V600E found in 25-50%; FDA-approved dabrafenib + trametinib (ROAR sub-cohort, Subbiah JCO 2018) — ORR ~69%. Time-critical: BRAF testing must return within days of diagnosis.

Used By

No reverse references found in the YAML corpus.